Semaglutide Does Not Increase Psychiatric Complications in Overweight, Obesity
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 3, 2024 -- Treatment with semaglutide does not increase the risk for developing symptoms of depression or suicidal ideation/behavior among adults with overweight or obesity, according to a study published online Sept. 3 in JAMA Internal Medicine.
Thomas A. Wadden, Ph.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined the psychiatric safety of subcutaneous semaglutide, once weekly, among people without known major psychopathology in a post-hoc analysis of pooled data from the multicenter, phase 3a STEP 1, 2, and 3 trials (3,377 participants) and phase 3b STEP 5 trial (304 participants), which included adults with overweight or obesity.
The researchers found that in the STEP 1, 2, and 3 trials, the mean baseline Patient Health Questionnaire (PHQ-9) scores were 2.0 and 1.8 for semaglutide and placebo, respectively, and the mean scores at week 68 were 2.0 and 2.4, respectively. Patients receiving semaglutide versus placebo were less likely to shift to a more severe category of PHQ-9 depression from baseline to week 68 (odds ratio, 0.63). Overall, 1 percent or fewer participants reported suicidal ideation/behavior during treatment based on the Columbia-Suicide Severity Rating Scale; no differences were seen between the semaglutide and placebo groups. Results were similar in STEP 5.
"Our new analyses provide assurance that the medication, when taken by individuals who are free of significant mental health concerns, does not increase the risk of depression, suicidal thoughts, or suicidal behavior," Wadden said in a statement.
Several authors disclosed ties to pharmaceutical and weight loss companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Chronic Exposure to Systemic Inflammation May Increase Risk for Affective Disorders
THURSDAY, July 3, 2025 -- For individuals with specific autoimmune conditions, there appears to be an increased risk for affective disorders, according to a study published online...
Late-Life Mood Disorders May Indicate Predisposition to Dementia
MONDAY, June 30, 2025 -- Alzheimer disease (AD) and diverse non-AD tau pathologies may contribute to late-life mood disorders (LLMDs), according to a study published online June 9...
Addictive Screen Use Tied to Suicidal Behaviors in Early Adolescence
FRIDAY, June 27, 2025 -- Both high and increasing addictive screen use trajectories are associated with suicidal behaviors and worse mental health in early adolescence, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.